Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

AIM ImmunoTech Inc.

NYSE: AIM · Life Sciences · 3 alerts · CIK 946644

Share price
$0.1310Close, Nov 16
Market cap
$5.23M
Shares outstanding
39.92MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All AIM ImmunoTech Inc. filings on SEC EDGAR ↗

4:36 PM ET 10-Q
Financial Results

AIM ImmunoTech Q3 2026 Results: Net Loss of $3.14M, Loss Narrows

AIM ImmunoTech reported a net loss of $9.95 million for the nine months ended September 30, 2026, compared to $9.78 million in the prior year. The company significantly strengthened its balance sheet through equity offerings and warrant exercises, increasing total assets to $9.75 million and achieving a positive stockholders' equity of $7.08 million.

Key figure
Net loss $3.14M
9:15 AM ET 8-K
Investor Presentation

AIM ImmunoTech Investor Presentation

AIM ImmunoTech Inc. has released a new corporate presentation titled 'The Ampligen Opportunity' along with a corresponding press release. The presentation outlines the company's strategic objectives and the clinical potential of its lead drug candidate, Ampligen, particularly in treating pancreatic cancer.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.